Tirzepatide and Atrial Fibrillation: What Does the Evidence Actually Say?

Does tirzepatide cause atrial fibrillation, or could it make it worse?

This is one of the questions our prescribers hear most often from patients managing an existing heart condition. The honest position is nuanced. AF was reported as an adverse event in some participants across the tirzepatide clinical programme, but the rates were not substantially higher than in placebo groups, and no causal link has been established. The Mounjaro SmPC on the electronic Medicines Compendium lists cardiac arrhythmia-related terms under post-marketing experience, meaning events have been reported in the real world (as they are for most medicines) without a confirmed frequency being established. That is meaningfully different from saying tirzepatide triggers AF.

What the broader evidence suggests is more encouraging. AF is closely tied to body weight: fat deposited around the heart changes atrial structure and electrical conduction, and losing a substantial amount of weight consistently reduces AF episode frequency in observational and interventional studies. Tirzepatide, in the SURMOUNT-1 trial published in the New England Journal of Medicine, produced an average body-weight reduction of around 20–21% at the 15 mg maintenance dose over 72 weeks. Weight loss of that magnitude is exactly the kind of intervention cardiologists and electrophysiologists advocate alongside rhythm-control strategies. You can read a fuller account of the UK trial evidence on our tirzepatide clinical trials overview.

Still, individual responses vary. Someone with persistent AF, reduced left-ventricular function, or a complex antiarrhythmic regimen sits in a different clinical position than someone with well-controlled paroxysmal AF on a single agent. The prescriber's job is to assess that distinction.

What does the cardiovascular trial programme actually cover?

The SURMOUNT programme was primarily designed to evaluate weight loss and metabolic outcomes, not cardiovascular safety as a primary endpoint. SURMOUNT-1 enrolled people with obesity or overweight plus at least one weight-related condition, and if you are considering joining a similar programme yourself, our page on the tirzepatide trial UK options explains what participation typically involves and who may be eligible. That means people with stable managed AF could appear in those cohorts, but the trials were not powered to detect differences in arrhythmia outcomes.

The dedicated cardiovascular outcomes data come from a separate programme. Our page on the tirzepatide cardiovascular outcomes trial covers this in detail, including what SURMOUNT-CVOT is examining in populations with established cardiovascular disease. Early signals from that data have been broadly reassuring, but the full read-out will sharpen the picture considerably. There is also a dedicated trial looking at tirzepatide in chronic kidney disease, another population where AF is disproportionately common, and interim data there have shown meaningful reductions in both weight and kidney-function decline.

The NHS England guidance on weight-management injections advises patients to tell their healthcare team about all existing conditions and medicines before starting, a straightforward step that matters more, not less, when the existing condition involves cardiac rhythm.

What should someone with AF consider before starting tirzepatide?

Several practical points are worth raising with a prescriber. First, anticoagulants. Most people with AF in the UK take a direct oral anticoagulant (apixaban, rivaroxaban, edoxaban or dabigatran) and these have relatively predictable absorption profiles that are unlikely to be materially disrupted by tirzepatide. Warfarin is different: INR can shift during periods of significant weight loss or any illness causing reduced intake, so more frequent monitoring is sensible. Raise this with whoever manages your anticoagulation.

Second, GI side effects. Nausea, reduced appetite and occasional vomiting are common at the start of tirzepatide treatment or after a dose increase, and these can affect hydration. Dehydration is a known AF trigger. Staying well hydrated, particularly during the early weeks, is not just general advice, for someone with AF it carries a specific rationale. The tirzepatide overview page covers the full side-effect profile including what to watch for.

Third, the medicines themselves. Some antiarrhythmics (flecainide and amiodarone in particular) have narrow therapeutic windows. Significant changes in body weight or GI transit can theoretically influence steady-state levels over time. This is not a reason to avoid treatment; it is a reason for the prescriber to know your full medicine list and for your GP to be informed when treatment starts. Our pharmacy notifies your GP in line with GPhC guidance as a standard part of the process, not an optional extra.

If you are thinking about the cost of private treatment as part of your decision, our weight-loss treatment overview explains what is included in the price and how the process works.

How does a prescriber assess someone with AF for tirzepatide?

At nume, every consultation is read by a GPhC-registered Independent Prescriber, a real clinician, not an automated triage system. For someone with AF, the relevant questions include which anticoagulant you take and how stable your INR or renal function is, whether your AF is paroxysmal or persistent, what other cardiac conditions are present, and whether any antiarrhythmic drugs with narrow therapeutic windows are in your regimen.

Photo-ID verification and live weight confirmation happen before any prescription is issued. Your GP is notified as standard. If treatment is approved, the pen arrives via DPD the next working day in a plain, unbranded box, indistinguishable from any other delivery, with full tracking on your phone. The clinical team remains available seven days a week if questions come up after you start.

Not every application will be approved, and that is by design. A prescriber who declines or asks for more information is doing their job. If you want to understand whether tirzepatide is likely to be suitable given your cardiac history, the right first step is a free consultation with our prescribers, there is no commitment, and our clinical team at nume can also point you toward our dedicated Mounjaro trial page if you would like to explore whether a structured trial pathway might be a better fit for your situation.